MPN Congress 2022 | The role of CALR mutations in the initiation and progression of MPNs
Ann Mullally
• 31 Oct 2022
Ann Mullally, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the role of calreticulin (CALR) mutations in the initiation and progression of myeloproliferative neoplasms (MPNs). Whilst it has been shown that CALR mutations alone are sufficient to initiate disease, their role in MPN progression remains unclear. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
